Claims for Patent: 10,532,047

Summary for Patent: 10,532,047

Title:	Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
Abstract:	The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.
Inventor(s):	George P. Luke
Assignee:	Forma Therapeutics Inc
Application Number:	US16/414,716
Patent Claims:	1. A solid form of Compound 1: characterized by an X-ray Powder Diffraction (XRPD) having diffractions at angles (2 theta±0.2) of 6.3, 12.8, 13.8, 23.6, and 27.8. 2. The solid form of claim 1 characterized by an X-ray Powder Diffraction (XRPD) having diffractions at angles (2 theta±0.2) of 6.3, 12.8, 13.8, 23.6, and 27.8, corresponding to d-spacing (angstroms±0.2) of 14.0, 6.9, 6.4, 3.8, and 3.2, respectively. 3. The solid form of claim 1 characterized by an X-ray Powder Diffraction (XRPD) having diffractions at angles (2 theta±0.2) of 5.7, 6.3, 8.5, 10.6, 12.8, 13.8, 17.3, 22.0, 22.8, 23.6, and 27.8. 4. The solid form of claim 1 characterized by an X-ray Powder Diffraction (XRPD) having diffractions at angles (2 theta±0.2) of 5.7, 6.3, 8.5, 10.6, 12.8, 13.8, 17.3, 22.0, 22.8, 23.6, and 27.8 corresponding to d-spacing (angstroms±0.2) of 15.4, 14.0, 10.4, 8.4, 6.9, 6.4, 5.1, 4.0, 3.9, 3.8, and 3.2, respectively. 5. The solid form of claim 1 characterized by an X-ray Powder Diffraction (XRPD) having peaks at the same or substantially the same angles (2θ±0.2) and corresponding d-spacing (ű0.2) of: d-spacing 2θ ± 0.2 Å ± 0.2 5.7 15.4 6.3 14.0 8.5 10.4 10.6 8.4 11.4 7.8 12.8 6.9 13.8 6.4 14.2 6.2 15.2 5.8 15.6 5.7 17.3 5.1 17.9 5.0 18.2 4.9 18.9 4.7 19.6 4.5 20.6 4.3 21.5 4.1 22.0 4.0 22.8 3.9 23.6 3.8 24.5 3.6 24.8 3.6 25.3 3.5 25.6 3.5 26.0 3.4 26.3 3.4 27.0 3.3 27.8 3.2 28.9 3.1 30.0 3.0 31.2 3.0 32.1 2.8 33.6 2.7 34.1 2.6 36.3 2.5 37.0 2.4 38.1 2.4 6. The solid form of claim 1 characterized by a differential scanning calorimetry (DSC) thermogram with an endothermic event observed at about 256.6° C. 7. The solid form of claim 2 characterized by a differential scanning calorimetry (DSC) thermogram with an endothermic event observed at about 256.6° C. 8. The solid form of claim 1 characterized by a dynamic vapor sorption (DVS) showing maximum water uptake of 0.25% w/w at 25° C./90% RH. 9. The solid form of claim 6 characterized by a dynamic vapor sorption (DVS) showing maximum water uptake of 0.25% w/w at 25° C./90% RH. 10. A solid form of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile, characterized by a DSC endothermic event at about 256.6° C., wherein the DSC is obtained by heating at 10° C./min from about 20° C. to about 300° C. using dry nitrogen to purge the system and the following parameters: Parameters DSC Pan Type Aluminum pan, closed Temperature RT-250° C. Ramp rate 10° C./min Purge gas N2 11. The solid form of claim 10 characterized by an X-ray Powder Diffraction (XRPD) having diffractions at angles (2 theta±0.2) of 6.3, 12.8, 13.8, 23.6, and 27.8. 12. The solid form of claim 10 characterized by a dynamic vapor sorption (DVS) showing maximum water uptake of 0.25% w/w at 25° C./90% RH. 13. The solid form of claim 11 characterized by a dynamic vapor sorption (DVS) showing maximum water uptake of 0.25% w/w at 25° C./90% RH. 14. A solid form of olutasidenib, characterized by at least one of the following characteristics: (i) an X-ray Powder Diffraction (XRPD) having diffractions at angles (2 theta±0.2) of 6.3, 12.8, 13.8, 23.6, and 27.8; (ii) a differential scanning calorimetry (DSC) thermogram with an endothermic event observed at about 256.6° C.; and (iii) a dynamic vapor sorption (DVS) showing maximum water uptake of 0.25% w/w at 25° C./90% RH. 15. The solid form of claim 14, characterized by an X-ray Powder Diffraction (XRPD) having diffractions at angles (2 theta±0.2) of 6.3, 12.8, 13.8, 23.6, and 27.8, corresponding to d-spacing (angstroms±0.2) of 14.0, 6.9, 6.4, 3.8, and 3.2, respectively. 16. The solid form of claim 15, characterized by an X-ray Powder Diffraction (XRPD) having diffractions at angles (2 theta±0.2) of 5.7, 6.3, 8.5, 10.6, 12.8, 13.8, 17.3, 22.0, 22.8, 23.6, and 27.8. 17. The solid form of claim 16, characterized by an X-ray Powder Diffraction (XRPD) having diffractions at angles (2 theta±0.2) of 5.7, 6.3, 8.5, 10.6, 12.8, 13.8, 17.3, 22.0, 22.8, 23.6, and 27.8 corresponding to d-spacing (angstroms±0.2) of 15.4, 14.0, 10.4, 8.4, 6.9, 6.4, 5.1, 4.0, 3.9, 3.8, and 3.2, respectively. 18. The solid form of claim 17, characterized by an X-ray Powder Diffraction (XRPD) having peaks at the same or substantially the same angles (2θ±0.2) and corresponding d-spacing (ű0.2) of: d-spacing 2θ ± 0.2 Å ± 0.2 5.7 15.4 6.3 14.0 8.5 10.4 10.6 8.4 11.4 7.8 12.8 6.9 13.8 6.4 14.2 6.2 15.2 5.8 15.6 5.7 17.3 5.1 17.9 5.0 18.2 4.9 18.9 4.7 19.6 4.5 20.6 4.3 21.5 4.1 22.0 4.0 22.8 3.9 23.6 3.8 24.5 3.6 24.8 3.6 25.3 3.5 25.6 3.5 26.0 3.4 26.3 3.4 27.0 3.3 27.8 3.2 28.9 3.1 30.0 3.0 31.2 3.0 32.1 2.8 33.6 2.7 34.1 2.6 36.3 2.5 37.0 2.4 38.1 2.4. 19. The solid form of claim 18, characterized by a differential scanning calorimetry (DSC) thermogram with an endothermic event observed at about 256.6° C. 20. The solid form of claim 19, characterized by a dynamic vapor sorption (DVS) showing maximum water uptake of 0.25% w/w at 25° C./90% RH.